Prevention of Incisional Hernia After Renal Transplantation
Launched by FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO RAMON Y CAJAL · Mar 9, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether using a special mesh to reinforce the closure of the surgical incision after a kidney transplant can help prevent a common complication called an incisional hernia. An incisional hernia occurs when tissue pushes through the abdominal wall at the site of the surgery, which can be uncomfortable and may require further treatment. The researchers will follow participants for two years after their transplant to see if this method reduces the number of people who develop hernias.
To be eligible for this trial, you must be planning to receive your first kidney transplant. Unfortunately, if you have had a kidney transplant before, you cannot participate. If you join the study, you will receive care as part of your transplant process, and you will be monitored to see how well the mesh reinforcement works in preventing incisional hernias. This trial is currently recruiting participants, and it is open to individuals aged 65 to 74, regardless of gender.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Candidate for first kidney transplant
- Exclusion Criteria:
- • Patient receiving a second or successive renal transplant.
About Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal
The Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal is a leading research organization dedicated to advancing biomedical science and enhancing patient care through innovative clinical trials. Located in Madrid, Spain, the foundation collaborates closely with healthcare professionals and academic institutions to facilitate cutting-edge research initiatives. Its mission is to foster a multidisciplinary approach to medical research, focusing on translating scientific discoveries into effective therapeutic strategies. By prioritizing patient safety and ethical standards, the foundation aims to contribute significantly to the global body of medical knowledge and improve health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Patients applied
Trial Officials
VICTORIA GOMEZ
Principal Investigator
Fundación para la Investigación Biomédica del Hospital Unive
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials